GLP-1 Side Effects: The Complete Guide

Most GLP-1 side effects are gastrointestinal: nausea, constipation, diarrhea, and bloating top the list, and the majority are mild to moderate and ease as your body adjusts. A smaller set of symptoms, like severe abdominal pain or signs of gallbladder trouble, are uncommon but worth knowing so you can act fast. This guide maps what is common, what is rare, when each tends to show up, and when a symptom crosses from "annoying" to "call your doctor."

GLP-1 medications like Ozempic/Wegovy (semaglutide) and Mounjaro/Zepbound (tirzepatide) work largely by slowing how fast your stomach empties and turning up satiety signals. That gastric-slowing mechanism, per the FDA Wegovy prescribing information and the StatPearls semaglutide overview, is the root cause of most of the GI side effects you will read about below.

Why GLP-1s cause side effects in the first place

GLP-1 receptor agonists slow gastric emptying, amplify gut and brainstem satiety signals, and dampen food-reward pathways. The same slowed digestion that helps you eat less also keeps food sitting in your stomach longer, which is why nausea, fullness, reflux, bloating, and constipation cluster together.

Here is the single most useful pattern to internalize: side effects are characteristically worst during dose titration and typically attenuate over weeks as your body adapts. The standard practice of escalating the dose slowly exists specifically to give your gut time to build tolerance. In the STEP trials, a pooled GI tolerability analysis (Wharton et al., Diabetes, Obesity and Metabolism 2022) found that the prevalence of GI events declined gradually over time rather than persisting at peak intensity.

That does not mean side effects vanish entirely at a steady dose. In STEP 4, GI adverse events were still reported in about 42% of people who continued semaglutide versus 26% who switched to placebo, so a lower-rate baseline can persist. But the trajectory for most people bends toward easier.

GLP-1 side effects by frequency, timeline, and what helps

The table below summarizes the most-discussed GLP-1 side effects, with incidence attributed to named trials and labels where a clean figure exists. Incidence figures vary by drug, dose, and how the data were pooled, so treat them as ranges, not promises. "Self-care levers" are general comfort measures, not treatment instructions.

Side effect	How common	Typical onset / duration	General comfort levers	Red flags to escalate
Nausea	Very common. Up to ~44% in clinical trials per the Wegovy label (aggregate); ~25% vs 9% placebo in pooled 3-trial data. Tirzepatide (SURMOUNT-1): ~25-33% by dose vs 9.5% placebo	Worst during dose escalation; usually eases over days to weeks	Smaller, lower-fat, protein-forward meals; eat slowly; stop before full	Persistent vomiting, signs of dehydration, inability to keep fluids down
Constipation	Common. Semaglutide ~17-24% per pooling; tirzepatide ~12-17% vs ~6% placebo (SURMOUNT-1)	Builds over the first weeks; can persist	Gradually add fiber, fluids, daily movement	No bowel movement with severe pain, vomiting, or a distended abdomen
Diarrhea	Common. Semaglutide ~23% vs 9% placebo; tirzepatide ~19-23% vs 7% placebo (SURMOUNT-1)	Often around dose increases; usually mild	Hydration and electrolytes; bland, lower-fat foods	Severe, bloody, or prolonged diarrhea; signs of dehydration
Vomiting	Common at higher doses. Tirzepatide ~8-12% vs 1.7% placebo (SURMOUNT-1)	Peaks during titration	Same as nausea; sip fluids	Persistent vomiting, can't stay hydrated
Abdominal pain / bloating	Common. Abdominal pain grouped ~16% vs 6% placebo (semaglutide pooled)	Variable; often with other GI effects	Smaller meals, ease up on fizzy and high-FODMAP foods	Severe or worsening pain, especially radiating to the back
Acid reflux / heartburn	Known GI effect, not cleanly enumerated in trial tables	Can appear early; tied to large or late meals	Stay upright after eating; avoid late large meals	Frequent or severe reflux despite changes
Sulfur ("egg") burps	Commonly reported by patients; no RCT incidence figure	Variable	Smaller, lower-fat meals; stay upright	With severe pain or persistent vomiting
Fatigue	Common. Semaglutide ~8-11% in trials	Often during early titration	Hit protein, hydrate, train	Sudden or severe fatigue; rule out other causes
Raised resting heart rate	Documented; mean +1-4 bpm vs placebo per Wegovy PI	Throughout treatment	Hydrate; check caffeine	Palpitations, chest pain, sustained high rate
Injection-site reactions	Low for semaglutide (~1%); higher for tirzepatide (up to ~10% itching/erythema in SURMOUNT)	After injections	Rotate sites; proper technique	Spreading redness, warmth, pus, allergic reaction
Hair shedding (telogen effluvium)	Reported ~3% semaglutide vs ~1% placebo (STEP 1)	Starts 2-4 months after rapid loss; usually self-limiting	Adequate protein, iron; slower loss	Persistent or patchy loss; check for deficiency
Gallstones	Cholelithiasis 1.6% vs 0.7% placebo (Wegovy trials)	Tied to rapid weight loss	Steadier pace; adequate protein and fat	Upper-right abdominal pain after fatty meals

Sources: Wegovy and Zepbound prescribing information; Wharton et al. (DOM 2022); SURMOUNT-1 GI tolerability (DOM 2025); JAMA Internal Medicine biliary meta-analysis (2022).

The most common side effects, in plain terms

Nausea

Nausea is the single most common GLP-1 side effect. Per the Wegovy prescribing information, up to roughly 44% of adults reported nausea across clinical trials (an aggregate figure); a tighter pooled 3-trial safety set put it at about 25% versus 9% on placebo. For tirzepatide in SURMOUNT-1, nausea ran from roughly 25% to 33% depending on dose, versus about 10% on placebo. Most events were mild to moderate, and nausea-driven discontinuation was uncommon (about 1.8% for semaglutide per the Wegovy label). Smaller, lower-fat, protein-forward meals tend to sit better. For a deeper playbook, see our guide on managing nausea on a GLP-1.

Constipation and diarrhea

Slowed gut motility can swing either way. Constipation affected roughly 17-24% on semaglutide depending on the pooling, and 12-17% on tirzepatide versus about 6% on placebo in SURMOUNT-1. Diarrhea was reported by about 23% on semaglutide and 19-23% on tirzepatide. The two can even alternate. Fiber, fluids, and movement are the first-line comfort levers for constipation; hydration and electrolytes matter most for diarrhea. We cover each in GLP-1 constipation relief and GLP-1 diarrhea causes and fixes.

Bloating, reflux, and sulfur burps

Because food lingers longer, gas and distension build up, and stomach acid has more time to creep upward. Bloating is often grouped under abdominal pain and discomfort in trial reporting (about 16% versus 6% placebo for semaglutide). Acid reflux and sulfur burps are well-recognized by patients and consistent with the gastric-slowing mechanism, even though clean trial incidence numbers are scarce.

The less-common side effects worth knowing

Fatigue

Fatigue showed up in roughly 8-11% of semaglutide users in trials. It is usually multifactorial: eating far less, losing fluids through GI symptoms, and a possible direct effect all contribute. Here is the nuance that matters for muscle: persistent weakness can also be an early muscle-loss signal from under-eating protein, which overlaps clinically with simple tiredness. If your energy is dropping while your strength is too, that is worth investigating, not just resting through.

Raised resting heart rate

All GLP-1 receptor agonists produce a small, consistent bump in resting heart rate. The Wegovy prescribing information notes mean increases of 1 to 4 beats per minute, and a tirzepatide meta-analysis in non-diabetic adults found a mean difference of about 2 bpm versus placebo. For most people the change is small and does not erase the cardiovascular benefits seen in trials like SELECT. Palpitations, chest pain, or a sustained high rate still warrant a medical check.

Hair shedding

GLP-1-associated hair loss is usually telogen effluvium, a temporary shift of hair follicles into a resting, shedding phase triggered by rapid, large-magnitude weight loss and the metabolic stress that comes with it. Alopecia was reported in about 3% of semaglutide users versus 1% on placebo in STEP 1. The drug is not directly toxic to hair; the rapid deficit and any nutritional gaps (iron, zinc, protein) are the primary drivers, which is why it typically presents 2-4 months in and resolves as weight stabilizes.

Gallstones

Cholelithiasis was reported in 1.6% of Wegovy trial participants versus 0.7% on placebo, and a 2022 JAMA Internal Medicine meta-analysis put the relative risk of biliary disease around 1.37, higher with higher doses. The main driver is rapid weight loss itself, a classic gallstone risk factor, with a possible secondary effect on gallbladder contractility. It is a real but relatively low absolute risk: know the warning sign (upper-right abdominal pain after fatty meals) and avoid crash-dieting.

When a side effect is an emergency

Most GLP-1 side effects are uncomfortable, not dangerous. A few are exceptions. Contact your prescriber or seek urgent care for severe, persistent abdominal pain (especially radiating to the back, a possible sign of pancreatitis), upper-right abdominal pain signaling gallbladder trouble, persistent vomiting or diarrhea with signs of dehydration, or any allergic reaction. The Wegovy prescribing information also notes rare cases of acute kidney injury linked to dehydration from GI events, which is why staying hydrated during a symptom flare matters.

The general rule: anything severe, anything that won't resolve, or anything that stops you eating and drinking is a reason to call, not to tough out.

Do side effects mean the drug is working?

This is one of the most persistent myths in the GLP-1 world, so it is worth stating plainly: side effects are not a reliable signal that the medication is working. Some people lose substantial weight with barely any nausea; others feel terrible and see average results. What actually tracks your progress is your weight trend and your body-composition data over weeks.

There is a related trap. Because fatigue and weakness can be either a passing drug side effect or an early sign you are losing muscle on a GLP-1, it helps to log them next to your strength and protein numbers. If "tired" lines up with falling protein intake and weaker lifts, that points toward muscle loss, not just a drug effect. Our guide on the signs you're losing muscle goes deeper on telling them apart.

This is where tracking earns its keep. In Myo, the side-effect log (11 symptoms rated 0-10, with notes) sits right next to your strength and lean-mass trends, so a passing drug side effect and a muscle-loss warning don't get mistaken for each other. Logging side effects against your dose week also shows when symptoms spike, so you can plan your easiest protein wins on the worst days instead of skipping food entirely.

The bottom line

The typical GLP-1 side-effect story is straightforward: mostly GI, mostly mild to moderate, worst during titration, and easing with time. A small number of red-flag symptoms deserve prompt attention. And because side effects say nothing about whether the drug is working, the data worth watching is your weight, your body composition, and your strength, not how queasy a dose increase made you feel. If a symptom is persistent, severe, or worrying, that is a conversation for your prescriber.

References

• FDA Wegovy Prescribing Information and StatPearls semaglutide overview (NCBI NBK603723)
• Wharton et al., Diabetes, Obesity and Metabolism 2022 (GI tolerability across STEP trials)
• SURMOUNT-1 GI tolerability, Diabetes, Obesity and Metabolism 2025
• Zepbound Prescribing Information (FDA accessdata)
• Nature / International Journal of Obesity GI meta-analysis 2025
• JAMA Internal Medicine biliary disease meta-analysis (PubMed 35344001)